Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2022 | Immune reconstitution after quadruplet therapy, autoSCT and MRD-adapted treatment cessation in NDMM

Luciano Costa, MD, PhD, UAB School of Medicine, Birmingham, AL, shares some insights into the findings of a correlative analysis on humoral immune reconstitution after quadruplet therapy, autologous transplantation, and measurable residual disease (MRD)-adapted treatment cessation in patients with newly diagnosed multiple myeloma (NDMM). This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.